AstraZeneca files Crestor/TriLipix combination
This article was originally published in Scrip
Executive Summary
AstraZeneca and Abbott have filed a US NDA for Certriad, a combination of AstraZeneca's Crestor (rosuvastatin calcium) and Abbott's TriLipix (fenofibric acid), for the treatment of mixed dyslipidaemia. The two firms have also entered into a co-promotion agreement for TriLipix, further strengthening the ties between them in the cardiovascular area – they already have an agreement whereby Abbott co-promotes Crestor in the US.